ADC Therapeutics
Viola Woo, MPH, is a seasoned professional in the fields of medical affairs and public health, currently serving as a Medical Affairs Coordinator at ADC Therapeutics since August 2021, where responsibilities include leading the compassionate use early access program and overseeing a portfolio of over 20 oncology Investigator Initiated Trials. Prior experience includes a role as a Public Health Adviser at NYC Health + Hospitals, where Viola managed case investigations and facilitated COVID-19 education, as well as a Health Policy Intern position at SUNY Downstate Medical Center, focusing on prostate cancer outreach. Additional roles encompass internships and research positions at reputable institutions such as NYSACHO, Icahn School of Medicine at Mount Sinai, Regeneron Pharmaceuticals, and Weill Cornell Medicine, demonstrating a strong background in research and public health initiatives. Viola holds a Master of Public Health in Health Policy and Management from SUNY Downstate Health Sciences University and a Bachelor of Science in Biomedical Sciences from the University at Buffalo.
This person is not in any offices
ADC Therapeutics
2 followers
ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.